Stabilitech's Proprietary Technology

Stabilitech’s core technology allows the stable storage of vaccines and other biological molecules at ambient temperature, removing the need for refrigeration. The technology also confers protection against both heat and freeze damage, and against the temperature fluctuations that often occur during transport and distribution of vaccines and biopharmaceuticals. Inspiration for the technology came from nature, which has already solved the challenge of stabilising complex biological materials against thermal and desiccation stress, as for example, in seeds. Stabilitech’s approach mimics some aspects of these natural principles and uses chemical excipients which are inexpensive, readily available and have already been used in a clinical setting. These excipients are typically either approved injectables, or have Generally Regarded As Safe status. The process can be readily integrated into existing cGMP manufacturing processes and involves freeze-drying using standard equipment.

Stabilitech technology has been shown to be applicable to the stabilisation of a wide range of live viruses (both enveloped and non-enveloped), inactivated viruses and sub-unit vaccines. Stabilitech technology has the potential for use in both human and animal vaccines.

Stabilisation of proteins and other unstable biological molecules has also been successfully achieved. So far, we have stabilised specific antibodies, enzymes, peptides and other proteins such as growth factors.

Stabilitech is the sole owner of all patents/patent applications pertaining to its Stabilisation Technology and the Company is actively involved in the expansion of its Intellectual Property portfolio.